AR108718A2 - COMPOSITION - Google Patents

COMPOSITION

Info

Publication number
AR108718A2
AR108718A2 ARP170101607A ARP170101607A AR108718A2 AR 108718 A2 AR108718 A2 AR 108718A2 AR P170101607 A ARP170101607 A AR P170101607A AR P170101607 A ARP170101607 A AR P170101607A AR 108718 A2 AR108718 A2 AR 108718A2
Authority
AR
Argentina
Prior art keywords
lipopolysaccharide
adjuvant
saponin
human dose
composition
Prior art date
Application number
ARP170101607A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR108718A2 publication Critical patent/AR108718A2/en

Links

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Dosis humana de una composición inmunogénica que comprende un antígeno o preparación antigénica, en combinación con un coadyuvante, comprendiendo dicho coadyuvante una fracción inmunológicamente activa de saponina derivada de la corteza de Quillaja Saponaria Molina presentada en forma de un liposoma y un lipopolisacárido, en el que dicha fracción de saponina y dicho lipopolisacárido están ambos presentes en dicha dosis humana a un nivel menor de 30 mg. Composición coadyuvante en un volumen adecuado para dosis humana que comprende entre 1 y 30 mg de un lipopolisacárido y entre 1 y 30 mg de una fracción inmunológicamente activa de saponina presentada en forma de un liposoma.Human dose of an immunogenic composition comprising an antigen or antigen preparation, in combination with an adjuvant, said adjuvant comprising an immunologically active fraction of saponin derived from the crust of Quillaja Saponaria Molina presented in the form of a liposome and a lipopolysaccharide, in which said saponin fraction and said lipopolysaccharide are both present in said human dose at a level less than 30 mg. Adjuvant composition in a volume suitable for human dose comprising between 1 and 30 mg of a lipopolysaccharide and between 1 and 30 mg of an immunologically active fraction of saponin presented in the form of a liposome.

ARP170101607A 2005-12-13 2017-06-13 COMPOSITION AR108718A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0525321.6A GB0525321D0 (en) 2005-12-13 2005-12-13 Novel compositions

Publications (1)

Publication Number Publication Date
AR108718A2 true AR108718A2 (en) 2018-09-19

Family

ID=35736013

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170101607A AR108718A2 (en) 2005-12-13 2017-06-13 COMPOSITION

Country Status (5)

Country Link
CN (1) CN101330924A (en)
AR (1) AR108718A2 (en)
GB (1) GB0525321D0 (en)
UA (1) UA98612C2 (en)
ZA (1) ZA200805025B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101690810B (en) * 2009-10-21 2011-08-17 辽宁益康生物股份有限公司 Tetravalent inactivated vaccine adjuvant against Newcastle Disease, infectious bronchitis, egg drop syndrome and bird flu and preparation method thereof
AR086405A1 (en) * 2011-05-17 2013-12-11 Glaxosmithkline Biolog Sa STREPTOCOCCUS PNEUMONIAE VACCINE
GB201213364D0 (en) * 2012-07-27 2012-09-12 Glaxosmithkline Biolog Sa Purification process
JP6290918B2 (en) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
CA2923030A1 (en) * 2013-10-03 2015-04-09 Nitto Denko Corporation Injectable vaccine composition
CN108853493A (en) * 2018-07-26 2018-11-23 中国人民解放军陆军军医大学 Ophiopogonin D and its nano-emulsion are preparing the application in vaccine adjuvant

Also Published As

Publication number Publication date
CN101330924A (en) 2008-12-24
UA98612C2 (en) 2012-06-11
GB0525321D0 (en) 2006-01-18
ZA200805025B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
AR058543A1 (en) NEW COMPOSITION OF VACCINE POTENTIATED WITH A LIPOSOMAL ASSISTANT
AR108718A2 (en) COMPOSITION
CY1121211T1 (en) HERPITAS VIRUS VACCINE
CO6440528A2 (en) ADJUTIVE COMPOSITIONS THAT INCLUDE A NON-IONIC ISOTONICITY AGENT.
CR11122A (en) WATER OIL EMULSION INFLUENZA VACCINE
ES2528665T3 (en) Manufacture of amplifying vaccines that have reduced antigen doses
CR10726A (en) VACCINE UNDERSTANDING AN OIL EMULSION WATER SUPPLIER
MX2010001054A (en) Antigen-adjuvant compositions and methods.
ECSP10010723A (en) MULTIVALLY NATIVE EXTERNAL MEMBRANE VESICLE VACCINE OF THE MENINGOCOCO, METHOD FOR MANUFACTURING AND USE
MXPA05013973A (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes.
FR11C0001I2 (en) COMBINED VACCINES AGAINST NEISSERIA MENINGITIDIS
AR048822A1 (en) MICROFLUIDIZED WATER OIL EMULSIONS AND VACCINE COMPOSITIONS
DK1748791T3 (en) Neisseria Meningitidis IgtB LOS as an adjuvant
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
ES2195169T3 (en) VACCINES AGAINST CALMIDIES AND IMMUNOGENIC COMPOSITIONS CONTAINING AN EXTERNAL MEMBRANE ANTIGEN AND METHODS FOR PREPARATION.
ECSP088636A (en) ANTIGENS OF DES-N-ACETYL-SIALIC ACID, ANTIBODIES FOR THE SAME, AND METHODS OF USE IN CANCER THERAPY
NO20023935L (en) New, non-antigenic mucosal adjuvant formulation that modulates the effects of substances including vaccine antigens in contact with mucosal body surfaces
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
AR054259A1 (en) VACCINE AGAINST HUMAN PAPILOMA VIRUS (HPV)
ECSP12011951A (en) USE OF A SOURCE OF L3 AND / OR L5 AS A VACCINE OR AS A DIAGNOSIS FOR A PARASITARY DISEASE
WO2010039924A3 (en) Th1 vaccination priming for active immunotheraphy
AR023536A1 (en) VACCINES
EP2433648A3 (en) Vaccine comprising an oil in water emulsion adjuvant
CR20110661A (en) ASSISTANT COMPOSITIONS THAT INCLUDE A NON-IONIC ISOTONICITY AGENT
DOP2009000068A (en) VACCINE UNDERSTANDING A WATER OIL EMULSION ASSISTANT

Legal Events

Date Code Title Description
FB Suspension of granting procedure